Berkshire Hathaway A earnings beat by $7.00, revenue topped estimates

Berkshire Hathaway A reported Q3 revenue of $105.6B versus the $100.93B consensus, a beat of about $4.67B. The article gives EPS of $15 and an analyst estimate of $8, yet describes EPS as $7 worse than the estimate; those figures are internally inconsistent. Shares had risen 11% over three months and 14% over 12 months, but the article does not attribute those gains to the results.

Analysis

The earnings signal is not tradeable as presented: the EPS figure and the stated estimate imply a beat arithmetically, while the article labels it a miss. For Berkshire, the distinction between operating earnings and GAAP results—where investment gains can create substantial noise—is also essential. Treat the headline and its sentiment as unverified until reconciled with the 10-Q and the relevant consensus definition; the promotional trading copy adds no evidence.

Near term, the main risk is a misread of the release driving a temporary price dislocation, not a clear change in Berkshire’s fundamentals. Over 1–3 months, verify insurance underwriting results, investment income, operating earnings by major segment, share repurchases, and cash levels. A broad equity drawdown could make Berkshire’s relative defensiveness more valuable, while weaker underwriting or a sustained decline in operating earnings would undermine that case. Over 6–18 months, capital allocation and insurance profitability matter more than a single quarter’s headline EPS. There is no defensible valuation or price target in the supplied data.

Key Decisions for Investors

• Do not trade the headline at the open. First reconcile EPS, the estimate basis, and operating versus GAAP earnings against Berkshire’s filing and a consistent consensus source.
• Set an alert—not an entry—if the shares materially underperform the broad market after the filing is verified; investigate whether the move reflects segment-level deterioration or simply investment-gain noise before taking exposure.
• For a 1–3 month thesis, consider a measured long BRK.A against broad equity exposure only if operating earnings and insurance results remain sound and the relative-price trend confirms. Define risk by closing-price underperformance versus the benchmark; do not infer a numeric stop from this article.
• Falsify the defensive thesis if the filing shows persistent operating-earnings weakness, deteriorating insurance underwriting, or capital allocation that fails to support per-share value. Reassess after the 10-Q and subsequent operating data; absent confirmation, no trade is warranted.